Showing 1 posts of 1 posts found.
Navidea Biopharmaceuticals, a developer of immunodiagnostic agents and immunotherapeutics, has announced that they will enter into a definitive asset purchase …
London secures major investment to accelerate healthcare innovation
People with severe mental illness more likely to die early from cardiovascular disease, report finds
Yourgene wins Australian approval for chemotherapy toxicity screening assay
ProBioGen secures extended GMP authorisation for viral manufacturing facility
PlaqueTec coronary disease trial reaches 100 patients across eight NHS centres